Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects

Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects

Abstract Background Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumours worldwide. Sorafenib (SOR) is one of the most effective single-drug systemic therapy against advanced HCC, but the identification of novel combination regimens for a continued improvement in ove...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ilaria Romito, Manuela Porru, Maria Rita Braghini, Luca Pompili, Nadia Panera, Annalisa Crudele, Daniela Gnani, Cristiano De Stefanis, Marco Scarsella, Silvia Pomella, Stefano Levi Mortera, Emmanuel de Billy, Adrian Libenzio Conti, Valeria Marzano, Lorenza Putignani, Manlio Vinciguerra, Clara Balsano, Anna Pastore, Rossella Rota, Marco Tartaglia, Carlo Leonetti, Anna Alisi
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
HCC
FAK
Sorafenib
Epigenetic
Therapy
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/4895e0e2b1b44fabbe5e18ca066750d0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/4895e0e2b1b44fabbe5e18ca066750d0

Ejemplares similares